Maine 2025 2025-2026 Regular Session

Maine Senate Bill SP0476 Introduced / Bill

                    Page 1 - 132LR2486(01)
STATE OF MAINE
_____
IN THE YEAR OF OUR LORD
TWO THOUSAND TWENTY-FIVE
_____
JOINT RESOLUTION DESIGNATING MAY 4, 2025 TO MAY 10, 
2025 AS TARDIVE DYSKINESIA AWARENESS WEEK
WHEREAS, 
schizophrenia often require treatment with antipsychotic medications for effective 
management, and antipsychotic prescribing rates continue to rise; and
WHEREAS, 
certain conditions, it is associated with tardive dyskinesia, or "TD," a condition marked by 
uncontrollable, abnormal and repetitive movements of the face, torso, limbs or extremities; and
WHEREAS, 
individuals, women, individuals with mood or substance use disorders, intellectual disabilities 
or central nervous system injuries and those with high cumulative antipsychotic exposure; and
WHEREAS, 
living with TD remain undiagnosed, and even mild TD symptoms can be stigmatizing and 
impair physical, social and emotional well-being, underscoring the urgency of early screening, 
detection and intervention; and
WHEREAS, 
their clinical guidelines for antipsychotic treatment, and individuals treated with antipsychotics 
or experiencing abnormal movements should consult their healthcare providers to assess TD 
risk, receive TD screenings and determine appropriate treatment together; and
WHEREAS, 
can provide options for symptom management and improved quality of life for many 
individuals living with TD; and
WHEREAS, 
for health care providers, patients and care partners to help ensure patients prescribed 
antipsychotics receive care and support that aligns with clinical best practice, including regular 
TD screenings; now, therefore, be it
RESOLVED: That We, the Members of the One Hundred and Thirty-second Legislature 
now assembled in the First Regular Session, on behalf of the people we represent, take this 
opportunity to designate May 4, 2025 to May 10, 2025 as Tardive Dyskinesia Awareness 
Week; acknowledge the importance of early detection and intervention to improve outcomes 
for people living with mental health conditions and prescribed antipsychotics; and express our 
support for efforts to raise awareness about the causes and symptoms of TD and the importance 
of routine TD screening.